SCHEMBL3528897

SCHEMBL3528897

CCNC(=O)c1cn(C2CCCCC2)c2nc(Nc3cccc(N4CCN(C)CC4)c3)ncc2c1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 15/20 0.66
WEE1 P30291 2/20 0.52
EGFR P00533 1/20 0.52
BTK Q06187 1/20 0.52
CDK4 P11802 2/20 0.47
NUAK1 O60285 1/20 0.47
CCND1 P24385 1/20 0.47
MARK3 P27448 1/20 0.47
CCND2 P30279 1/20 0.47
CCND3 P30281 1/20 0.47
MARK2 Q7KZI7 1/20 0.47
MARK4 Q96L34 1/20 0.47
NUAK2 Q9H093 1/20 0.47
MARK1 Q9P0L2 1/20 0.47
AURKA O14965 1/20 0.47
INSR P06213 1/20 0.47
CDK1 P06493 1/20 0.47
PDGFRB P09619 1/20 0.47
SRC P12931 1/20 0.47
PDGFRA P16234 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529808 0.92 CSF1R (0.69) CSF1RWEE1EGFRBTKCDK4
SCHEMBL3530652 0.91 CSF1R (0.80) CSF1RWEE1CDK4NUAK1CCND1
SCHEMBL4772999 0.90 CSF1R (0.71) CSF1RWEE1EGFRBTKCDK4
SCHEMBL3527194 0.89 CSF1R (0.82) CSF1RWEE1EGFRBTKCDK4
SCHEMBL3527206 0.89 CSF1R (0.65) CSF1RWEE1EGFRBTKCDK4
SCHEMBL3534995 0.83 CSF1R (0.86) CSF1RINSRPDGFRBSRC
SCHEMBL3530165 0.82 CSF1R (0.83) CSF1RWEE1CDK4NUAK1CCND1
SCHEMBL4767401 0.81 CSF1R (0.86) CSF1RWEE1EGFRCDK4NUAK1
SCHEMBL3530467 0.80 CSF1R (1.00) CSF1RWEE1CDK4NUAK1CCND1
SCHEMBL3530132 0.80 CSF1R (0.79) CSF1RWEE1CDK4NUAK1CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US claimed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP claimed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO claimed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US claimed
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR CSF1R 427/4885WEE1 154/4885EGFR 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.